EP Patent

EP3962365A4 — THERAPEUTIC AND PROPHYLACTIC USE OF MITOCHONDRIA AND COMBINED MITOCHONDRIAL AGENTS

Assigned to Boston Childrens Hospital · Expires 2023-02-01 · 3y expired

What this patent protects

Patent listed against elamipretide-hydrochloride.

Drugs covered by this patent

elamipretide-hydrochloride (ELAMIPRETIDE HYDROCHLORIDE)

Patent Metadata

Patent number: EP3962365A4
Jurisdiction: EP
Classification: —
Expires: 2023-02-01
Drug substance claim: No
Drug product claim: No
Assignee: Boston Childrens Hospital
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.